Xenetic Biosciences (XBIO) Capital Expenditures (2014 - 2025)
Xenetic Biosciences' (XBIO) quarterly Capital Expenditures came in at $313921.0 in Q4 2025, up 144.56% YoY from $128359.6 in Q4 2024, and up 144.56% on a QoQ basis from -$704431.0 in Q4 2024.
Xenetic Biosciences (XBIO) Capital Expenditures (2014 - 2025) Analysis & Trends
Xenetic Biosciences (XBIO) has 9 years of Capital Expenditures data on file, last reported at $313921.0 in Q4 2025.
- Quarterly Capital Expenditures rose 144.56% year-over-year to $313921.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$390510.0 (up 44.56% YoY) and the FY2024 annual result came in at -$704431.0, down 1350.07% from the prior year.
- Capital Expenditures advanced to $313921.0 in Q4 2025, from -$704431.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $387501.0 in Q4 2021 to a low of -$704431.0 in Q4 2024.
- A 5-year average of -$7658.8 and a median of $0.0 in 2022 frame the typical range for Capital Expenditures.
- The widest YoY moves for Capital Expenditures: up 192.62% in 2023, down 7849.91% in 2023.
- Tracing XBIO's Capital Expenditures over 5 years: stood at $387501.0 in 2021, then tumbled by 187.46% to -$338920.0 in 2022, then surged by 192.62% to $313921.0 in 2023, then tumbled by 324.4% to -$704431.0 in 2024, then jumped by 144.56% to $313921.0 in 2025.
- The last three Capital Expenditures figures came in at $313921.0 (Q4 2025), -$704431.0 (Q4 2024), and $313921.0 (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Xenetic Biosciences | 8.01 Mn | 1.54 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 313,921.00 |
| Dec 31, 2025 | 313,921.00 |
| Dec 31, 2024 | -704,431.00 |
| Dec 31, 2024 | -704,431.00 |
| Dec 31, 2023 | 313,921.00 |
| Dec 31, 2023 | 313,921.00 |
| Jun 30, 2023 | -140,000.00 |
| Jun 30, 2023 | -140,000.00 |
| Mar 31, 2023 | -222,500.00 |
| Mar 31, 2023 | -222,500.00 |
| Dec 31, 2022 | -338,920.00 |
| Dec 31, 2022 | -338,920.00 |
| Sep 30, 2022 | 313,920.00 |
| Sep 30, 2022 | 313,920.00 |
| Jun 30, 2022 | -2,871.00 |
| Jun 30, 2022 | -2,871.00 |
| Mar 31, 2022 | 2,871.00 |
| Mar 31, 2022 | 2,871.00 |
| Dec 31, 2021 | 387,501.00 |
| Dec 31, 2021 | 387,501.00 |